Health and Fitness Health and Fitness
Tue, April 30, 2013
Mon, April 29, 2013
Sun, April 28, 2013
Fri, April 26, 2013
Thu, April 25, 2013
Wed, April 24, 2013
Tue, April 23, 2013
Mon, April 22, 2013
Sun, April 21, 2013
Fri, April 19, 2013
Thu, April 18, 2013
Wed, April 17, 2013
Tue, April 16, 2013
Mon, April 15, 2013
Fri, April 12, 2013
Thu, April 11, 2013
[ Thu, Apr 11th 2013 ] - Market Wire
15 PM EDT
Wed, April 10, 2013
Tue, April 9, 2013
[ Tue, Apr 09th 2013 ] - Market Wire
30 a.m. ET
Mon, April 8, 2013
Sat, April 6, 2013
Fri, April 5, 2013
Thu, April 4, 2013
Wed, April 3, 2013

KaloBios' Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"


//health-fitness.news-articles.net/content/2013/ .. cussion-of-new-defenses-against-old-enemies.html
Published in Health and Fitness on Wednesday, April 17th 2013 at 20:00 GMT by Market Wire   Print publication without navigation


KaloBios' Targeted Antibacterial KB001-A to be Featured in BIO 2013... -- SOUTH SAN FRANCISCO, Calif., April 17, 2013 /PRNewswire/ --

SOUTH SAN FRANCISCO, Calif., April 17, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: [ KBIO ]) today announced that David Pritchard , President and Chief Executive Officer, will speak at the BIO 2013 International Convention in Chicago, IL on Tuesday, April 23 as part of a panel entitled, "New Defenses Against Old Enemies: Vaccines and Biotherapies for Bacterial Infection."

(Logo: [ http://photos.prnewswire.com/prnh/20130225/MM66380LOGO ])

Mr. Pritchard will be discussing the company's targeted antibacterial agent against Pseudomonas aeruginosa (Pa), KB001-A. KaloBios is developing KB001-A for the management of Pa in the lungs of patients with cystic fibrosis, while the company's corporate partner Sanofi Pasteur is developing KB001-A for the prevention of ventilator-associated pneumonia caused by Pa.

Breakout Session: Innovations and Opportunities in Vaccines
Session ID 1877: New Defenses Against Old Enemies: Vaccines and Biotherapies for Bacterial Infection
When:Tuesday, April 23, 2013, 9:00 – 10:15 AM
Where: McCormick Place, Room S402A

About KaloBios

KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat serious medical conditions with a primary clinical focus on respiratory diseases and cancer.  For more information on KaloBios Pharmaceuticals, please visit our web site at [ http://www.kalobios.com ].

Contact:
Jeffrey H. Cooper
Chief Financial Officer
KaloBios Pharmaceuticals, Inc.
(650) 243-3146
[ ir@kalobios.com ]

Media Contact:
Joan E. Kureczka
Kureczka/Martin Associates
Tel:  (415) 821-2413
Mobile: (415) 690-0210
[ Joan@Kureczka-Martin.com ]

SOURCE KaloBios Pharmaceuticals



RELATED LINKS
[ http://www.kalobios.com ]

Publication Contributing Sources